<DOC>
	<DOCNO>NCT00986245</DOCNO>
	<brief_summary>1 . In order compare benefit , side effect , patient preference Ropinirole prolong release use once-daily twice-daily dose 2 . In order estimate conversion rate dopamine agonists Ropinirole prolong release</brief_summary>
	<brief_title>Study Compare Effect Ropinirole Prolonged Release Once-daily Versus Twice-daily</brief_title>
	<detailed_description>1 . Study subject : Parkinson disease Ropinirole immediate release Pramipexole immediate release consider change Ropinirole prolong release 2 . Cross study design : - Group 1 : daily dose 2 month twice daily divide dose 2 month - Group 2 : twice daily divide dose 2 month daily dose 2 month 3 . Dose adjustment may do first 4 week . 4 . Compare benefit , side effect , patient preference daily v twice daily dose .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>1 . Age : 3080 2 . Parkinson disease 3 . On dopamine agonist ( Ropinirole IR Pramipexole IR ) consider change Ropinirole PR 4 . On stable antiparkinsonian medication least 4 week 5. Who sign consent study 1. Who less 2 mg Ropinirole IR 0.375 mg Pramipexole IR 2. Who dementia , psychosis , major depression serious neurological medical problem 3. Who allergic similar medication 4. Who history heavy metal poison 5. Who othe clinical trial medication within last 4 week 6 . Whoa pregnant lactate 7. Who consider eligible investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Parkinson disease</keyword>
	<keyword>Ropinirole</keyword>
</DOC>